Skip to main content
Category

News Archive

Ignar and Robinson

BioHealth Innovation Adds Diane Ignar, Ph.D. and Dr. Loleta Robinson as NIH New Entrepreneurs-in-Residence

By News Archive

Ignar and RobinsonBiohealth and Entrepreneur Experts Joins Robust Entrepreneurs-in-Residence (EIR) Team

ROCKVILLE, MARYLAND, August 23, 2021 BioHealth Innovation Inc. (BHI) announces the addition of Diane Ignar, Ph.D., and Dr. Loleta Robinson to the expanding Entrepreneurs-in-Residence (EIR) team. The Entrepreneur-in-Residence Program at BHI ensures that disruptive technologies receive all the resources required to transform the technology from a discovery into a commercially relevant product and eventually have a measurable impact on human health. The program was created to support scientists, early-stage startups, and licensed technologies to provide them with access to these resources. Diane will work with NIH’s National Institute on Aging, and Loleta will work with their Office of Extramural Research.

 “BHI is pleased to welcome Diane and Loleta to our growing group of EIRs working with the National Institutes of Health,” said Richard Bendis, BHI President, and CEO. “Their backgrounds in healthcare, venture capital, and helping early-stage businesses are key to our mission for the program nationally, and regionally.”

Read More
University of Maryland UM Ventures Logo

Empower Therapeutics Inc. Granted Exclusive License to Develop Digital Therapeutics Platform for Neuromodulation of Pain Sensitivity

By News Archive

University of Maryland UM Ventures Logo

BALTIMORE, Aug. 19, 2021 /PRNewswire/ — Empower Therapeutics Inc., a Baltimore-based startup, has secured worldwide, exclusive rights to a simple, reliable brainwave biomarker for pain sensitivity. Empower plans to leverage the technology, which is jointly owned by the University of Maryland, Baltimore (UMB) and the University of Birmingham, U.K., to develop a cutting-edge digital therapeutics platform to determine and modify pain sensitivity for chronic pain therapy.   

 

Read More

Alexandria Chairman Joel Marcus On Emerging Cities, Megacampuses And ‘Hucksters’

By News Archive

Courtesy of Alexandria Real Estate Equities
Alexandria Real Estate Equities Chairman Joel Marcus

When Joel Marcus, a trained accountant and biotech industry lawyer, started lab real estate giant Alexandria Real Estate Equities in the 1990s, the sure bet many see in biotech wasn’t visible to many. The company’s first leases in San Francisco charged lab tenants just $6 per SF. Now, the REIT’s average tenant pays just shy of $70.  

Image: Courtesy of Alexandria Real Estate Equities Alexandria Real Estate Equities Chairman Joel Marcus

Read More
NewImage

Implementing GMP For Early-Phase Development With Cartesian Therapeutics Co-Founder And CEO Dr Murat Kalayoglu

By News Archive

NewImage

A key factor in the success of a developing drug or therapy is the success of early clinical trials. A focus on Good Manufacturing Practice (GMP) standards for phase 1, first-in-human trials is critical to maximize the chances of success from a project’s start. For cell therapy development, where even small errors can make a big difference, it’s even more important.

 

Read More

Johns Hopkins Tech Ventures startups saw $1B in investment in fiscal 2021 – Baltimore Business Journal

By News Archive

Johns Hopkins Technology Ventures operates several FastForward startup accelerator programs for student-led ventures and other growing spinout companies.
KAITLIN NEWMAN</p>

<p>

Startups with ties to Johns Hopkins ties have contributed significantly to the highest-ever amounts of capital being raked in across Maryland and beyond. For example, three spinout companies raised mega-deals in fiscal 2021, or venture deals worth $100 million or more.

Image: Johns Hopkins Technology Ventures operates several FastForward startup accelerator programs for student-led ventures and other growing spinout companies. KAITLIN NEWMAN  

Read More
Cursor and Notification Center

Johns Hopkins Technology Ventures – Fiscal Year 2021 Annual Report

By News Archive

Cursor and Notification Center

I’m pleased to share with you JHTV’s annual report for Fiscal Year 2021. The pandemic made FY21 an unusual one, but the JHTV team made it an extraordinary one, as the report demonstrates. We took full advantage of the momentum that had been building prior to the pandemic and used our digital connectivity to continue bringing the benefits of academic discovery to the world. Among our FY21 achievements:

BXP Logo

BXP Life Sciences Expands with Montgomery County, Maryland Acquisition – BioHealth Capital Region

By News Archive

BXP Logo

BOSTON – July 27, 2021 – Boston Properties, Inc. (NYSE: BXP), the largest publicly traded developer, owner, and manager of Class A office properties in the United States, announced today that it has agreed to purchase the Shady Grove Bio+Tech Campus in Rockville, Maryland. The property includes seven existing buildings comprising approximately 435,000 square feet across 31 acres in the Shady Grove life sciences cluster, a highly desirable location for leading and emerging companies in the biotechnology sector.

 

Read More
Carol Nacy

50 Over 50 2021: Vision

By News Archive

Carol NacyArmed with brilliant ideas, experience and a determination to disrupt, these 50 women are making an impact on society and culture through healthcare, robotics, music, dance, and so much more. It’s the third chapter of our 50 Over 50 project, launched in June and produced in partnership with Mika Brzezinski’s Know Your Value initiative.

 

Read More

Sonosa Medical Spins Out of the MDC Studio

By News Archive

Sonosa

The MDC Studio is pleased to announce the spin-out of the company, Sonosa Medical, Inc., as an independent entity. Founded in 2019, Sonosa Medical is developing next-generation devices poised to transform the diagnosis and treatment of obstructive sleep apnea (OSA). The company is led by Dr. Stephen Restaino as Chief Executive Officer, Dr. Jeffrey Wolf as Medical Advisor, and Dr. Gil Blankenship as Chairman of the Board. Dr. Restaino and his team have been developing novel technology for the detection and treatment of OSA using a wearable device. Their work has been funded by a $3.35 million Phase II Small Business Innovation Research (SBIR) award from the Defense Advanced Research Projects Agency (DARPA).

 

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.